SAGE Therapeutics (SAGE) Misses Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
November 12, 2019 6:31 AM ESTZULRESSO (brexanolone) CIV injection revenues of $1.5M in third quarter
Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively
Planning to expand pipeline with two new GABA and NMDA clinical-stage assets
Conference call today at 8:00 a.m. EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today, Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the... More
